Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2021-05-12 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于召开2021年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2021 first extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, attendance, and proxy voting instructions. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is about 3094 characters, which is relatively short and consistent with a meeting notice. There is no indication that this is a full report or results announcement. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to prepare for voting at the meeting.
2021-05-12 Chinese
圣湘生物科技股份有限公司关于购买资产的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 圣湘生物科技股份有限公司 regarding the purchase of 18.63% shares of 上海科华生物工程股份有限公司. It includes transaction details, parties involved, financial data, strategic rationale, and regulatory compliance statements. The content focuses on a capital acquisition transaction, describing the share purchase agreement, payment terms, and impact on company control and financials. It is not a financial report, earnings release, or management discussion, but a formal announcement of a capital/financing update related to a significant asset purchase. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive update on financing activity.
2021-05-12 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东股份被司法冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the judicial freezing of shares held by a shareholder owning more than 5% of the company's stock. It details the legal circumstances, the number of shares frozen, the courts involved, and the impact on the company. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. This is a regulatory announcement about a shareholder's shareholding status and legal issues affecting those shares. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-05-11 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东股份被司法冻结的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the judicial freezing of shares held by a shareholder owning more than 5% of the company's stock. It details the freezing circumstances, the parties involved, and the impact on the company. There is no financial data, report, or presentation included. The document is a regulatory announcement about a major shareholding event, specifically the freezing of shares of a significant shareholder. This fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on this specific event, not a full report or financial statement.
2021-05-06 Chinese
圣湘生物科技股份有限公司关于持股5%以上股东股份被司法冻结的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the judicial freezing of shares held by a shareholder owning more than 5% of the company's stock. It details the frozen shares, the courts involved, and the reasons for the freezing, which relate to personal loan disputes of the shareholder. The document does not contain financial statements, management discussion, or any report data. It is a regulatory announcement about a shareholder's shareholding status and legal restrictions on those shares. This fits the category of Major Shareholding Notification (MRQ), as it concerns a significant shareholder's shares being frozen and the impact on shareholding and control. The document length is short and focused on this specific event, not a full report or financial disclosure.
2021-05-05 Chinese
圣湘生物科技股份有限公司关于自愿披露公司新冠抗原检测试剂获得德国及希腊白名单注册的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of the registration of a COVID-19 antigen test product in Germany and Greece. It discusses product registration details, market competition risks, and uncertainties about profit impact. There is no financial data, no mention of financial results, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no earnings information. The document is a regulatory announcement informing the market about product registration and associated risks. It is short (1446 characters) and does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.